CPRX

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Coral Gables, Florida, focused on developing and commercializing therapies for rare neuromuscular and neurological diseases. The company's lead product, Firdapse (amifampridine phosphate), is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Catalyst is also developing treatments for other rare conditions including congenital myasthenic syndromes and spinal muscular atrophy. The company specializes in identifying underserved patient populations and bringing therapeutic solutions to market for these rare disease communities.